Veda Giri, MD, on innovative approaches to genetic testing in prostate cancer
In a recent interview with Urology Times®, Veda N. Giri, MD, outlined alternative care models that could help…
Genomic testing helps inform treatment intensity decisions in intermediate-risk prostate cancer
Data from a large real-world analysis presented at the American Society for Radiation Oncology 67th Annual Meeting1 suggests…
Veda Giri, MD, on barriers to genetic testing in prostate cancer
In a recent interview with Urology Times®, Veda N. Giri, MD, outlined some of the key barriers to…
Key takeaways from the COMRADE trial in CRPC, with Rana McKay, MD
Findings from the phase 2 COMRADE trial (NCT03317392)were recently shared at the 2025 American Society of Clinical Oncology Annual…
Referral rates for genetic counseling in renal cell carcinoma remain low
Although national guidelines recommend genetic counseling for all patients with early-onset or bilateral renal cell carcinoma (RCC), the…
Urine biomarker assay outperforms PCA3 in prostate cancer diagnosis
A team of investigators from Johns Hopkins Kimmel Cancer Center, Johns Hopkins All Children’s Hospital, and 4 collaborating…
ACS report shows prostate cancer remains a significant public health challenge
The American Cancer Society (ACS) has published its annual Prostate Cancer Statistics, 2025 report, showing increasing incidence rates…